Safety of elevated pulmonary doses from [177Lu]Lu-PSMA-617 and 90Y-radioembolization therapies

被引：0
|
作者：
Jain, S. [1 ]
Graves, S. A. [1 ]
机构：
[1] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-1229
引用
收藏
页码：S919 / S919
页数：1
相关论文
共 50 条
  • [31] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
  • [32] Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling
    Spitz, Avery
    Floyd, Rebecca
    Sutton, Jennifer
    Gardner, Linda
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2023, 27 (05) : 539 - 547
  • [33] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Buck, Andreas K.
    Rowe, Steven P.
    Higuchi, Takahiro
    Seitz, Anna Katharina
    Kuebler, Hubert
    Schirbel, Andreas
    Essler, Markus
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (09) : 3269 - 3276
  • [34] [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 RLT in challenging advanced mCRPC patients
    Rosar, F.
    Krause, J.
    Bartholomae, M.
    Maus, S.
    Stemler, T.
    Hierlmeier, I.
    Linxweiler, J.
    Ezziddin, S.
    Khreish, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S315 - S315
  • [35] Characterization of Non-Specific Uptake and Retention Mechanisms of [177Lu]Lu-PSMA-617 in the Salivary Glands
    Heynickx, Nathalie
    Segers, Charlotte
    Coolkens, Amelie
    Baatout, Sarah
    Vermeulen, Koen
    PHARMACEUTICALS, 2023, 16 (05)
  • [36] Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
    Rosar, Florian
    Schon, Niklas
    Bohnenberger, Hendrik
    Bartholoma, Mark
    Stemler, Tobias
    Maus, Stephan
    Khreish, Fadi
    Ezziddin, Samer
    Schaefer-Schuler, Andrea
    EJNMMI PHYSICS, 2021, 8 (01)
  • [37] A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer
    Jia, Angela Y.
    Spratt, Daniel
    LANCET ONCOLOGY, 2024, 25 (10): : 1246 - 1247
  • [38] Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [177Lu]Lu-PSMA-617 in Healthy Organs
    Mueller, Marco
    Lucaroni, Laura
    Favalli, Nicholas
    Bassi, Gabriele
    Neri, Dario
    Cazzamalli, Samuele
    Oehler, Sebastian
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (10) : 8247 - 8260
  • [39] [177Lu]Lu-PSMA-617 (Pluvicto™): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
    Hennrich, Ute
    Eder, Matthias
    PHARMACEUTICALS, 2022, 15 (10)
  • [40] Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
    Florian Rosar
    Niklas Schön
    Hendrik Bohnenberger
    Mark Bartholomä
    Tobias Stemler
    Stephan Maus
    Fadi Khreish
    Samer Ezziddin
    Andrea Schaefer-Schuler
    EJNMMI Physics, 8
12345